KPV
At a Glance
KPV is a tripeptide (Lys-Pro-Val) often discussed as melanocortin-derived and explored in inflammatory bowel disease (IBD) model systems. A key line of work reports PepT1-mediated uptake and reduced inflammatory signaling in cell and mouse colitis models. [PMID: 18061177]
⚠️ Research Status: KPV is not an approved medication. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
In experimental work, KPV has been studied as a peptide that can be transported by PepT1 and associated with reduced inflammatory pathway activation in intestinal epithelial and immune cell contexts. [PMID: 18061177]
Evidence Summary
Low Confidence Animal Study 3-10 YearsIn cell systems and two mouse colitis models, oral KPV administration was associated with reduced inflammatory signaling and cytokine expression in the studied paradigms. [PMID: 18061177]
Safety & Unknowns
- Human clinical efficacy and safety are not established by preclinical models.
- Effects may be context-dependent (e.g., PepT1 expression and inflammatory milieu).
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved |
| European Union (EMA) | Not approved |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |